Pharmaceutical - Asia-Pacific, Sanofi

Filter

Current filters:

Asia-PacificSanofi

Popular Filters

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

19-03-2014

In a second collaboration in less than a month, Sanofi Pasteur, the vaccines division of French drug…

Asia-PacificLicensingPharmaceuticalResearchSanofiSanofi PasteurSK ChemicalVaccines

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

New Zealand reaches agreement with Sanofi to fund ALS drug

11-09-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with…

Asia-PacificNeurologicalPharmaceuticalRare diseasesRegulationRilutekSanofi

China starts investigation of alleged bribery by Sanofi

12-08-2013

Following last week's whistleblower allegations that French drug major Sanofi (Euronext: SAN) had paid…

Asia-PacificLegalMarkets & MarketingPharmaceuticalPricingSanofi

Sanofi latest to be implicated Chinese bribery allegations

09-08-2013

In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

New Zealand to widen access for type 1 and type 3 Gaucher disease drug

07-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Takeda gains Chinese approval for diabetes drug

31-07-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

India's NPPA says drugmakers cannot raise prices of imported products

10-05-2013

At a meeting earlier this month, India's drug price regulator the National Pharmaceutical Pricing Authority…

AllerganAsia-PacificNovartisPharmaceuticalPricingSanofi

Sanofi to invest $75 million in Vietnam facility; views Chinese expansion

03-04-2013

French drug major Sanofi (Euronext: SAN) announced the official launch of a construction project for…

Asia-PacificPharmaceuticalProductionSanofi

Sanofi eyes big plans for China

11-02-2013

French pharmaceutical giant Sanofi (Euronext: SAN) plans to complete building a large plant for the production…

Asia-PacificPharmaceuticalProductionSanofiSanofi PasteurVaccines

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24-01-2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Japan's seasonal flu vaccines market analysis

16-01-2013

The Japanese influenza vaccine market is valued at around $702 million in 2012, according to a new report…

Anti-viralsAsia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalSanofiVaccines

Australian launch for Sanofi Pasteur's Imojev, first single-dose vaccine against Japanese encephalitis

11-12-2012

Sanofi Pasteur, the vaccines division of Sanofi (Euronext: SAN) has launched its Imojev vaccine against…

Asia-PacificImojevMarkets & MarketingPharmaceuticalSanofiSanofi PasteurVaccines

Sanofi MS drug Aubagio gets second approval, in Australia

21-11-2012

Having already gained approval in the largest global pharma market, the USA, French drug major Sanofi's…

Asia-PacificAubagioBiotechnologyGenzymeNeurologicalPharmaceuticalRegulationSanofi

Chugai licenses SGLT2 inhibitor CSG452 in Japan to Kowa and Sanofi

29-10-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

Asia-PacificChugai PharmaceuticalCSG452DiabetesKowa PharmaceuticalsLicensingPharmaceuticalRocheSanofi

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

23-10-2012

French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Analyst insight: Sanofi eyes Columbia, Indonesia and Vietnam

20-09-2012

Emerging markets, BRIC countries are words that have recently risen to prominence in a majority of pharmaceutical…

Asia-PacificLicensingMarkets & MarketingMergers & AcquisitionsPharmaceuticalSanofiSouth America

New Zealand's PHARMAC agrees pricing deal with Sanofi for Arava

04-09-2012

New Zealand's national pharmaceuticals funding agency, PHARMAC, has announced changes to the listings…

Anti-Arthritics/RheumaticsAravaAsia-PacificLeflunomidePharmaceuticalPricingSanofi

Sanofi moves on Lemtrada; Novartis Indian patent case

21-08-2012

French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Sanofi files for Japanese approval of diabetes drug Lyxumia

11-06-2012

French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi inaugurates Lantus SoloSTAR Pen assembly plant in China

28-05-2012

French drug major Sanofi (Euronext: SAN) revealed this morning that it has inaugurated a new assembling…

Asia-PacificDiabetesLantusMarkets & MarketingPharmaceuticalSanofi

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015

22-11-2011

The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant

07-10-2011

French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme says that the results of a pivotal…

Asia-PacificAubagioFinancialGenzymeNeurologicalPharmaceuticalResearchSanofiShanthaVaccines

Company Spotlight

ImmunoGen

ImmunoGen

Back to top